Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine

Leukemia

Volumn 28, Issue 3, 2014, Pages 621-628

  Valencia, A ^a   Masala, E ^a   Rossi, A ^a   Martino, A ^b   Sanna, A ^a   Buchi, F ^a   Canzian, F ^b   Cilloni, D ^c   Gaidano, V ^c   Voso, M T ^d   Kosmider, O ^e,f   Fontenay, M ^e,f   Gozzini, A ^a   Bosi, A ^a   Santini, V ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF TURIN   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f INSTITUT COCHIN   (France)

Author keywords

Azacitidine; Myelodysplastic syndromes; Resistance; UCK1

Indexed keywords

AZACITIDINE; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; DEOXYCYTIDINE KINASE GENE; DNA POLYMORPHISM; DRUG METABOLISM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 GENE; FEMALE; GENE; GENE EXPRESSION; GENE LOCUS; GENE SEQUENCE; GENE SILENCING; HUMAN; MALE; METHYLATION; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; RRM1 GENE; RRM2 GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; UCK1 GENE; UCK2 GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AZACITIDINE; ENZYME INHIBITORS; ENZYMES; FEMALE; GENE SILENCING; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NUCLEOSIDES; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 84895785721     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.330     Document Type: Article

References (47)

1. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized, controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429-2440.
2. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
3. Raj K, John A, Ho A, Chronis C, Khan S, Samuel J et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-Azacytidine. Leukemia 2007; 21: 1937-1944.
4. Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Testoni N et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci USA 2009; 106: 16811-16816.
5. Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A et al. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget 2012; 3: 490-501.
6. Voso MT, Fabiani E, Piciocchi A, Matteucci C, Brandimarte L, Finelli C et al. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine. Leukemia 2011; 25: 1910-1913.
7. Follo MY, Finelli C, Mongiorgi S, Clissa C, Chiarini F, Ramazzotti G et al. Synergistic induction of PI-PLCb1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Leukemia 2011; 25: 271-280.
8. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28: 605-613.
9. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; 25: 1147-1152.
10. Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 2014; 28: 78-87.
11. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P et al. Prognostic factors for response and overall survival in 282 patients with higherrisk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117: 403-411.
12. Sorm F, Piskala A, Cihak A, Veselý J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964; 20: 202-203.
13. Santini V. Azacitidine: Activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. Expert Rev Hematol 2009; 2: 121-127.
14. Rius M, Stresemann C, Keller D, Brom M, Schirrmacher E, Keppler D et al. Human concentrative nucleoside transporter 1-mediated uptake of 5-Azacytidine enhances DNA demethylation. Mol Cancer Ther 2009; 8: 225-231.
15. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larráyoz I, Martínez-Picado J et al. Cell entry and export of nucleoside analogues. Virus Res 2005; 107: 151-164.
16. Lee T, Karon M, Momparler RL. Kinetic studies on phosphorylation of 5-Azacytidine with the purified uridine-cytidine kinase from calf thymus. Cancer Res 1974; 34: 2482-2488.
17. Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-Azacytidine on L1210 leukemia. Cancer Res 1970; 30: 2760-2769.
18. Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S et al. RNA-dependent inhibition of ribonucleotidereductase is a major pathway for 5-Azacytidine activity in acute myeloid leukemia. Blood 2012; 119: 5229-5238.
19. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010; 5: E9001.
20. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: Mechanisms of drug resistance and reversal strategies. Leukemia 2001; 15: 875-890.
21. Veuger MJ, Honders MW, Spoelder HE, Willemze R, Barge RM. Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines. Leuk Res 2003; 27: 445-453.
22. Galmarini CM, Thomas X, Graham K, El Jafaari A, Cros E, Jordheim L et al. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol 2003; 122: 53-60.
23. Galmarini CM, Graham K, Thomas X, Calvo F, Rousselot P, El Jafaari A et al. Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 2001; 98: 1922-1926.
24. Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 2005; 93: 1388-1394.
25. Rathe SK, Largaespada DA. Deoxycytidine kinase is downregulated in Ara-Cresistant acute myeloid leukemia murine cell lines. Leukemia 2010; 24: 1513-1515.
26. Yin B, Tsai ML, Hasz DE, Rathe SK, Le Beau MM, Largaespada DA. A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia. Leukemia 2007; 21: 1093-1097.
27. Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A et al. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-Azacytidine or decitabine therapy. Clin Cancer Res 2013; 19: 938-948.
28. Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I et al. Myelodysplastic syndromes. In: Swederlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC): Lyon, France, 2008, pp 87-107.
29. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
30. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
31. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649.
32. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
33. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
34. Buchi F, Spinelli E, Masala E, Gozzini A, Sanna A, Bosi A et al. Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. Leuk Res 2012; 36: 607-618.
35. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
36. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52-57.
37. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C et al. Aberrant DNA methylationis a dominant mechanism in MDS progression to AML. Blood 2009; 113: 1315-1325.
38. Kulasekararaj AG, Mohamedali AM, Smith AE. Polycomb complex group gene mutations and their prognostic relevance in 5-Azacitidine treated myelodysplastic syndrome patient blood. Blood 2010; 116: (abstract 125
39. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008; 123: 8-13.
40. Momparler RL, Derse D. Kinetics of phosphorylation of 5-Aza-2'-deoxyycytidine by deoxycytidine kinase. Biochem Pharmacol 1979; 28: 1443-1444.
41. Qin T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One 2011; 6: E23372.
42. Saiki Y, Yoshino Y, Fujimura H, Manabe T, Kudo Y, Shimada M et al. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem Biophys Res Commun 2012; 421: 98-104.
43. Van Rompay AR, Norda A, Lindén K, Johansson M, Karlsson A. Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol 2001; 59: 1181-1186.
44. Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V et al. Pharmacogenetics of deoxycytidine kinase: Identification and characterization of novel genetic variants. J Pharmacol Exp Ther 2007; 323: 935-945.
45. Veuger MJ, Honders MW, Landegent JE, Willemze R, Barge RM. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood 2000; 96: 1517-1524.
46. Tattersall MH, Ganeshaguru K, Hoffbrand AV. Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside. Br J Haematol 1974; 27: 39-46.
47. Albertioni F, Lindemalm S, Reichelova V, Pettersson B, Eriksson S, Juliusson G et al. Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-Triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res 1998; 4: 653-658..